brentuximab vedotin + cyclophosphamide + doxorubicin + vincristine + prednisone

This is a multi-agent chemotherapy regimen combining **brentuximab vedotin**, **cyclophosphamide**, **doxorubicin**, **vincristine**, and **prednisone**. - **Brentuximab vedotin** is an antibody-drug conjugate targeting CD30-expressing cells, delivering a cytotoxic agent (MMAE) to induce apoptosis. - **Cyclophosphamide** is an alkylating agent interfering with DNA replication. - **Doxorubicin** is an anthracycline antibiotic that intercalates DNA and generates free radicals, leading to DNA damage. - **Vincristine** is a vinca alkaloid disrupting microtubule polymerization during mitosis. - **Prednisone** is a synthetic glucocorticoid, exerting anti-inflammatory and immunosuppressive effects. This combination is used primarily for the treatment of **classical Hodgkin lymphoma** (specifically, high-risk, previously untreated pediatric patients) and is being studied or utilized in certain CD30-positive peripheral T-cell lymphomas. The regimen is sometimes abbreviated as **BV+CHP** (when vincristine is included; when etoposide is also included, it is AVEPC or CHEP-BV) and is based on established protocols for aggressive lymphomas[1][2][4][5].